A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Grail's cancer test misses primary study goal in UK study
Grail's cancer test misses primary study goal in UK study
AbbVie, PhRMA can proceed with 340B case in Hawaii
AbbVie, PhRMA can proceed with 340B case in Hawaii
When a health tech startup gets stuck in regulatory limbo
When a health tech startup gets stuck in regulatory limbo
Teva beats Corcept in appeals fight over generic Cushing's syndrome drug
Teva beats Corcept in appeals fight over generic Cushing's syndrome drug
FDA formalizes one pivotal trial policy via NEJM perspective
FDA formalizes one pivotal trial policy via NEJM perspective
Obesity biotech Verdiva plans big year of data, explores deals
Obesity biotech Verdiva plans big year of data, explores deals
Biogen stops part of an MS trial; Merck reports more Enflonsia data
Biogen stops part of an MS trial; Merck reports more Enflonsia data
Sanofi to expand in India; Stada invests $100M in Saudi Arabia
Sanofi to expand in India; Stada invests $100M in Saudi Arabia
Hims to buy Australia’s Eucalyptus for $240M upfront in global push
Hims to buy Australia’s Eucalyptus for $240M upfront in global push
Altesa raises $75M for oral respiratory med
Altesa raises $75M for oral respiratory med
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
Why clinical AI startup Kintsugi shut down
Why clinical AI startup Kintsugi shut down
Senate health committee chair plots future FDA changes
Senate health committee chair plots future FDA changes
Pharma is done negotiating as Trump pushes to codify deals
Pharma is done negotiating as Trump pushes to codify deals
J&J pours $1B into new cell therapy site in Pennsylvania
J&J pours $1B into new cell therapy site in Pennsylvania
Charles River highlights increase in demand as tariff uncertainties fade
Charles River highlights increase in demand as tariff uncertainties fade
Updated: Novartis signs macrocyclic deal with Unnatural Products
Updated: Novartis signs macrocyclic deal with Unnatural Products
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page